Heartware International, Inc. (HTWR): James Schuermann , SVP, Sales & Marketing of Heartware International, Inc. sold 1,000 shares on Jul 1, 2016. The Insider selling transaction was reported by the company on Jul 5, 2016 to the Securities and Exchange Commission. The shares were sold at $57.77 per share for a total value of $57,770.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 4, 2016, James Schuermann (SVP, Sales & Marketing) sold 1,000 shares at $31.36 per share price.On Feb 26, 2016, Peter F Mcaree (SVP, CFO and Treasurer) sold 697 shares at $29.49 per share price.Also, On Feb 26, 2016, Mark Strong (Senior VP, R&D and Quality) sold 395 shares at $29.67 per share price.On Feb 26, 2016, Jeffrey Larose (Chief Scientific Officer) sold 354 shares at $29.48 per share price.
Shares of HeartWare International Inc (HTWR) ended Friday, Jul 1, 2016 session in red amid volatile trading. The shares closed down -0.2 points or -0.35% at $57.55 with 7,14,284 shares getting traded. Post opening the session at $57.63, the shares hit an intraday low of $57.51 and an intraday high of $57.94 and the price vacillated in this range throughout the day. The company has a market cap of $1,009 M and the number of outstanding shares has been calculated to be 1,75,40,557 shares. The 52-week high of HeartWare International Inc is $94.15 and the 52-week low is $25.015.
Company has been under the radar of several Street Analysts.HeartWare International Inc is Downgraded by Wells Fargo to Market Perform. Earlier the firm had a rating of Outperform on the company shares. The Rating was issued on Jun 29, 2016.HeartWare International Inc is Downgraded by SunTrust to Neutral. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on Jun 28, 2016.HeartWare International Inc is Initiated by Guggenheim to Neutral. The Rating was issued on Jun 9, 2016.HeartWare International Inc is Reiterated by Barclays to Overweight while Lowering the Price Target of the company shares to $ 35 from a previous price target of $42 . The Rating was issued on May 5, 2016.
Heartware International Inc. is a medical device company. The Company develops and manufactures miniaturized implantable heart pumps or ventricular assist devices for patients suffering from advanced heart failure. The HeartWare Ventricular Assist System (HVAD System) which includes a ventricular assist device (VAD) or blood pump patient accessories and surgical tools provides circulatory support for patients in the advanced stage of heart failure. The core of the HVAD System is a continuous flow blood pump the HVAD pump. The HVAD System is designed to be implanted adjacent to the heart avoiding abdominal surgery directly adjacent to the heart. The Company’s hybrid system is used for suspending the impeller. The impeller is suspended within the pump housing by the opposing forces of passive magnets and hydrodynamic thrust generated by the pump impeller which circulates a cushion of blood.